Sugi Predict

Sugi Predict / Targets / CFB

CFB

Complement factor B · P00751 · CFB on Sugi Atlas →

8,392 patent compounds predicted against CFB, 4,719 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5929015 SCHEMBL5929015 0.50 12/20
SCHEMBL7655150 SCHEMBL7655150 0.54 10/20
SCHEMBL803692 SCHEMBL803692 0.56 9/20
SCHEMBL7655142 SCHEMBL7655142 0.43 9/20
SCHEMBL3707241 SCHEMBL3707241 0.36 8/20
SCHEMBL10188885 SCHEMBL10188885 0.45 7/20
SCHEMBL11017363 SCHEMBL11017363 0.42 7/20
SCHEMBL10976711 SCHEMBL10976711 0.34 7/20
SCHEMBL10976714 SCHEMBL10976714 0.34 7/20
SCHEMBL10979251 SCHEMBL10979251 0.56 6/20
SCHEMBL11020318 SCHEMBL11020318 0.45 6/20
SCHEMBL7653331 SCHEMBL7653331 0.45 6/20
SCHEMBL13677328 SCHEMBL13677328 0.44 6/20
SCHEMBL5039014 SCHEMBL5039014 0.40 6/20
SCHEMBL13660561 SCHEMBL13660561 0.39 6/20
SCHEMBL4949268 SCHEMBL4949268 0.36 6/20
SCHEMBL8523197 SCHEMBL8523197 0.36 6/20
SCHEMBL11187565 SCHEMBL11187565 0.58 5/20
SCHEMBL6054523 SCHEMBL6054523 0.57 5/20
SCHEMBL8693621 SCHEMBL8693621 0.57 5/20

Clinical trials — most relevant to CFB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation PHASE3COMPLETED
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children PHASE3UNKNOWN
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) PHASE2WITHDRAWN
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis PHASE2COMPLETED
Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy PHASE2NOT_YET_RECRUITING
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation PHASE1/PHASE2WITHDRAWN
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab PHASE2WITHDRAWN
TP10 Use in Patients With C3 Glomerulopathy (C3G) PHASE1WITHDRAWN
First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers PHASE1COMPLETED
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation PHASE1COMPLETED
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD nanCOMPLETED
Genetic Load and Phenotype in Aggressive AMD nanCOMPLETED
Role of Renal Artery Doppler in Critically Ill Children With Acute Kidney Injury nanUNKNOWN
The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration nanCOMPLETED
Complement Activation in the Lysosomal Storage Disorders nanWITHDRAWN
Transcriptome and Metabolic Analyses of CHAPLE Disease nanUNKNOWN
Complement C5a Receptors in Hidradenitis Suppurativa nanCOMPLETED
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration nanCOMPLETED
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome nanCOMPLETED
Individualised Postprandial Glucose Responses in Type 1 Diabetes nanCOMPLETED
Complement and Graft-versus-host Disease nanCOMPLETED
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study nanACTIVE_NOT_RECRUITING
Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2 nanCOMPLETED
DKK-3 rs11544814 and CFH rs10737680 Polymorphism and Protein Levels With Non Surgical Periodontal Therapy in Periodontitis Patients With and Without CAD nanUNKNOWN
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays nanUNKNOWN
Investigating Meningococcal Vaccines in Adults nanCOMPLETED
Effect of Platelet Storage on Complement Activation nanUNKNOWN
Immune System in Diabetic Kidney Disease nanENROLLING_BY_INVITATION
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry nanRECRUITING
Anesthetic Management and Remote Reperfusion Injuries nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CFB binder may also engage these)

ProteinNameSimilarity
P04186 — 1.000 P04186 →
P81187 — 1.000 P81187 →
Q864W1 — 1.000 Q864W1 →
Q864V9 — 1.000 Q864V9 →
Q8SQ75 — 1.000 Q8SQ75 →
Q864W0 — 1.000 Q864W0 →
P06681 — 1.000 P06681 →
Q8SQ74 — 1.000 Q8SQ74 →
Q03710 — 0.999 Q03710 →
Q863A0 — 0.997 Q863A0 →
P21180 — 0.996 P21180 →
Q3SYW2 — 0.994 Q3SYW2 →
Q5R1W3 — 0.987 Q5R1W3 →
Q10743 — 0.984 Q10743 →
Q69DK8 — 0.984 Q69DK8 →
Q8CFG9 — 0.984 Q8CFG9 →
EPHA5 Ephrin type-A receptor 5 0.984 landscape →
Q5E9Z2 — 0.983 Q5E9Z2 →
F10 Coagulation factor X 0.983 landscape →
P18292 — 0.983 P18292 →
Q75ZY9 — 0.982 Q75ZY9 →
Q2QLA9 — 0.982 Q2QLA9 →
Q03145 — 0.982 Q03145 →
P49150 — 0.982 P49150 →
Q09YK0 — 0.982 Q09YK0 →
Q108U6 — 0.982 Q108U6 →
F2 Prothrombin 0.982 landscape →
Q6L711 — 0.982 Q6L711 →
P00735 — 0.981 P00735 →
Q8IWY4 — 0.981 Q8IWY4 →